Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Aditya BardiaXichun HuRebecca DentKan YonemoriCarlos H BarriosJoyce A O'ShaughnessyHans WildiersJean-Yves PiergaQingyuan ZhangCristina SauraLaura BiganzoliJoo Hyuk SohnSeock-Ah ImChristelle LévyWilliam JacotNatasha BegbieJun KeGargi PatelCurigliano Giuseppenull nullPublished in: The New England journal of medicine (2024)
Among patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer who had received one or more lines of endocrine-based therapy, treatment with trastuzumab deruxtecan resulted in longer progression-free survival than chemotherapy. No new safety signals were identified. (Funded by AstraZeneca and Daiichi Sankyo; DESTINY-Breast06 ClinicalTrials.gov number, NCT04494425.).